Order Article Reprints

Kokkali S, Saloustros E, Stefanou D, Makrantonakis P, Kentepozidis N, Boukovinas I, Xenidis N, Katsaounis P, Ardavanis A, Ziras N, et al. Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group. Current Oncology. 2022; 29(2):1237-1251. https://doi.org/10.3390/curroncol29020105

Kokkali, Stefania, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras, and et al. 2022. "Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group" Current Oncology 29, no. 2: 1237-1251. https://doi.org/10.3390/curroncol29020105

Kokkali, S., Saloustros, E., Stefanou, D., Makrantonakis, P., Kentepozidis, N., Boukovinas, I., Xenidis, N., Katsaounis, P., Ardavanis, A., Ziras, N., Christopoulou, A., Rigas, G., Kalbakis, K., Vardakis, N., Emmanouilides, C., Athanasiadis, I., Anagnostopoulos, A., Hatzidaki, D., Prinarakis, E., ... Georgoulias, V. (2022). Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group. Current Oncology, 29(2), 1237-1251. https://doi.org/10.3390/curroncol29020105